QURE Stock — uniQure N.V.: Cash, EV, Pipeline

Share price

$44.00

Market cap

$3,052.1M

Cash

$413.0M

Enterprise value

$2,689.0M

Balance sheet

Cash	$413.0M
Debt	$49.9M
Net cash	$363.1M
Enterprise value	$2,689.0M
Basic shares	69.3M shares
Fully diluted shares	80.2M shares
Fully diluted market cap	$3,529.1M
Cash per share	$5.96

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading QURE daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	AMT-191	Phase 2	Fabry Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

AMT-130

Phase 1 · Active Modality: AAV gene therapy (miQURE miRNA gene-silencing)

Target huntingtin (HTT)

Indications

Huntington's disease (Phase 1)

Catalysts

— Q3 2026

Status note Phase I/II trials in the US and Europe; FDA aligned June 2026 that a BLA under the accelerated approval pathway is reasonable; confirmatory study design pending alignment.

AMT-260

Phase 1 · Active Modality: AAV gene therapy

Target GRIK2

Indications

refractory mesial temporal lobe epilepsy (MTLE) (Phase 1)

Status note GenTLE Phase I/IIa trial ongoing; first cohort enrollment completed 2025.

AMT-191

Phase 1 · Active Modality: AAV gene therapy

Target GLA (from 10-K fallback)

Indications

Fabry disease (Phase 1)

Status note Phase I/II trial ongoing; GLA target from 10-K fallback (target/modality only).

AMT-162

Phase 1 · Active Modality: AAVrh10 gene therapy (miRNA)

Aliases APB-102

Target SOD1

Partnerships Apic Bio (global license)

Indications

SOD1-ALS (Phase 1)

Status note EPISOD1 Phase I/II enrollment voluntarily paused September 2025 upon IDMC recommendation after a dose-limiting toxicity; data collection from the 5 dosed patients continues; no discontinuation disclosed.

HEMGENIX

Approved · Active Modality: AAV gene therapy

Target factor IX

Partnerships CSL Behring (global commercialization rights; uniQure receives royalties and manufacturing income)

Indications

hemophilia B (Approved)

Status note Economic asset via the global CSL Behring license; royalty and manufacturing income.

Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	AMT-130
Lead indication	Huntington's disease
Lead phase	Phase 1/2
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06100276	Phase 2	Active, not recruiting	Sponsor	QURE	—	Amyotrophic Lateral Sclerosis	—
NCT06063850	Phase 2	Recruiting	Sponsor	QURE	—	Mesial Temporal Lobe Epilepsy	—
NCT06270316	Phase 2	Recruiting	Sponsor	QURE	—	Fabry Disease	—
NCT05243017	Phase 2	Active, not recruiting	Sponsor	QURE	—	Huntington Disease	September 2026
NCT04120493	Phase 2	Active, not recruiting	Sponsor	QURE	—	Huntington's Disease	September 2026

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for UniQure Biopharma B.V. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	3,941,572	+1,355,216	1.55%	2026-08-14
OrbiMed Advisors	1,807,486	-328,663	1.58%	2026-08-14
ADAR1 Capital Management	324,672	+248,466	0.70%	2026-08-14
Braidwell LP	301,652	+301,652	0.51%	2026-08-14
Logos Global Management	30,000	+30,000	0.06%	2026-08-14
Ikarian Capital	0	-91,060	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

QURE — uniQure N.V.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders